- In April 2024, B. Braun SE, a prominent German healthcare solutions provider, launched its next-generation absorbable bone wax product designed to reduce postoperative complications and improve hemostasis during orthopedic and neurosurgical procedures. This new formulation focuses on enhanced biocompatibility and ease of application, reinforcing the company’s commitment to surgical innovation and safety. The product launch positions B. Braun to strengthen its footprint in both developed and emerging markets
- In March 2024, Medtronic plc announced the expansion of its bone hemostatic product line with the introduction of a synthetic, fully bioresorbable bone wax, targeting trauma and spinal surgeries. This development aims to address the clinical demand for advanced materials that minimize infection risks and do not interfere with bone healing. The strategic move is part of Medtronic’s broader push toward developing next-gen surgical consumables in response to growing surgeon and patient preferences
- In February 2024, Johnson & Johnson Private Limited introduced its novel non-absorbable bone wax stick in select Asia-Pacific markets, emphasizing controlled application and long shelf-life. The launch was accompanied by clinical training initiatives across major hospitals in India and Southeast Asia. This step highlights the company’s strategy to expand its product accessibility and improve surgical outcomes in high-volume healthcare settings
- In January 2024, Bentley Healthcare Pvt. Ltd. (India) unveiled an economical bone wax solution tailored for emerging markets. The product, available in both natural and synthetic variants, was developed in response to increased demand for cost-effective surgical consumables in rural and semi-urban hospitals. Bentley’s initiative aligns with the government’s "Make in India" campaign and targets large-volume orthopedic and trauma centers
- In December 2023, WNDM Medical Inc. (U.S.) received FDA clearance for its biodegradable bone wax formulation, marking a milestone in sustainable surgical innovation. The new wax aims to offer superior hemostatic performance while eliminating the risk of long-term foreign body reactions. The company announced plans to roll out the product in U.S. hospitals and expand into EU markets by mid-2025
- In November 2023, Abyrx Inc. announced strategic collaborations with leading neurosurgical centers in the U.S. to conduct real-world evaluations of its next-gen absorbable bone hemostats. These studies focus on comparing efficacy, wound healing time, and surgeon preference. The initiative reflects Abyrx’s dedication to evidence-based product refinement and establishing clinical benchmarks in bone hemostasis
